Do You Have a Recurrent High-Grade Glioma or Diffuse Midline Glioma?
Diffuse midline gliomas are the most aggressive brain tumors for children and young adults. Most people with these tumors survive less than 2 years. Researchers want to see if they can measure the amount of anti-cancer drug, Abemaciclib in a brain tumor and brain fluid after a patient has taken this drug for a few days. These findings can help explain how much drug gets into the brain and how drugs work to shrink high grade gliomas to improve outcomes for these patients.
You may participate if you:
- Are ages 18 to 39 years old
- Have a recurrent high-grade glioma or diffuse midline glioma (DMG)
- Are not pregnant or breastfeeding
During the study, you will:
- Have tests of heart function, chest X-rays and MRI brain imaging
- Take drug Abemaciclib twice a day for 4 and a half days (9 doses)
- Get a tumor biopsy or surgical resection where part or all of your tumor will be removed
- Inpatient stay of 3-4 days at the Clinical Center, located in Bethesda, MD
- Have routine follow-ups if you continue with maintenance therapy
All tests and procedures are provided at no cost. Travel and lodging may be provided.
To learn more, call:
NIH Clinical Center Office of Patient Recruitment
800-411-1222
(TTY users dial 7-1-1)
Email: ccopr@nih.gov
Or go online:
https://bit.ly/3S6MCIG
Refer to study #22-C-0003
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)